The Pulse of Progress: METAvivor President Kelly Shanahan on the Frontlines of Metastatic Breast Cancer Research

Introduction: The Volatility of Life and Science

In the world of metastatic breast cancer (MBC), the only constant is change. Dr. Kelly Shanahan, President of METAvivor, describes this reality with the poignant volatility of her home in Lake Tahoe: one day the sun shines with the promise of summer, and the next, a sudden, biting snowfall obscures the view. For those living with MBC, this meteorological metaphor is a daily lived experience. In her latest presidential address, Dr. Shanahan offers a comprehensive look at the state of metastatic research, the shifting regulatory landscape, and the urgent, ongoing fight to turn Stage 4 cancer into a manageable, long-term condition.

Main Facts: A Surge in Research Interest

The most significant indicator of the current climate in oncology research is the sheer volume of interest in the METAvivor grant cycle. This year, the Scientific Advisory Board (SAB) was tasked with reviewing 200 letters of intent (LOIs)—a figure that mirrors last year’s record-breaking numbers and doubles the historical average.

Dr. Shanahan notes that this surge is not merely a sign of academic curiosity; it is a direct reflection of the instability currently plaguing federal research funding. As Dr. Stuart Martin, a veteran member of the SAB, remarked, METAvivor has become a critical lifeline, ensuring that metastasis research maintains momentum during a period of unprecedented fiscal uncertainty.

The process, while rigorous, is designed to be collaborative. Following the initial screening, the most promising proposals will undergo a comprehensive review process involving both scientific experts and Patient Advocate Reviewers (PARs). This dual-layer evaluation ensures that while the science is cutting-edge, it remains tethered to the actual, lived needs of the patient community.

Chronology of Advocacy and Innovation

The calendar for the coming months is dense with critical milestones for the breast cancer community.

Late May (ASCO 2024): The focus shifts to Chicago for the American Society of Clinical Oncology (ASCO) annual meeting. Dr. Shanahan has been invited to take the "big stage," presenting on the vital necessity of patient-centered endpoints in clinical trial design.
May 2024 (Regulatory Wins): The FDA marked a historic month with multiple approvals. Notably, the approval of vepdegestrant for ER+, HER2- MBC with ESR1 mutations, and datopotamab deruxtecan (dato-DXd) as a first-line treatment for metastatic TNBC patients ineligible for immunotherapy. Additionally, the expanded indication for Enhertu (trastuzumab deruxtecan) in early-stage HER2+ patients aims to proactively reduce the risk of future metastatic progression.
Mid-June: Dr. Shanahan will travel to Minnesota for the Hormel Institute’s Global Cancer Consortium. The focus here is on the "hallmarks of metastasis," featuring keynote insights from SAB member Dr. Danny Welch.

Supporting Data: The Regulatory Tug-of-War

The complexity of modern oncology is perhaps best exemplified by the recent discussions surrounding the drug camizestrant.

The Oncologic Drugs Advisory Committee (ODAC) recently voted not to recommend the transition from standard AI + CDK4/6 inhibitor therapy to a regimen involving camizestrant for patients with ESR1 mutations prior to imaging-confirmed progression. This decision sparked significant debate within the patient and medical communities.

Dr. Shanahan, alongside board members Janice Cowden and Lynda Weatherby, provided deep analysis of this decision on the Live from Stage 4 podcast. The friction arises from a fundamental question: how should regulatory bodies integrate new, sensitive technology—such as identifying mutations via liquid biopsy—into clinical decision-making?

While the FDA continues to review the data, there is a global disparity in approach. The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has already recommended the approval of camizestrant based on the SERENA-6 trial. This divergence highlights a global tension: how quickly can we adopt life-saving, targeted therapies without sacrificing the rigor of traditional clinical trials?

Official Responses: Elevating the Patient Voice

The central theme of Dr. Shanahan’s advocacy is the "bigger table" philosophy. Too often, clinical trials are designed with endpoints that satisfy regulatory requirements but ignore the quality-of-life concerns of the people actually taking the medication.

In her upcoming ASCO presentation, "How to design trials that are meaningful to people with cancer," Dr. Shanahan intends to challenge the status quo. Quoting the Spice Girls’ iconic "tell me what I want, what I really, really want," she underscores a simple but radical premise: researchers must ask patients what they value most. Whether it is a reduction in toxicity, the preservation of cognitive function, or the ability to maintain daily routines, these "patient-centered endpoints" are the missing link in modern drug development.

This call for inclusion extends to the METAvivor grant review process. The organization is actively seeking more scientists and, crucially, more patient advocates to serve as reviewers. By democratizing the grant-making process, METAvivor ensures that research funding is directed toward projects that offer the greatest potential for meaningful survival.

Implications: The Path Toward a New Paradigm

The current landscape of MBC research is characterized by a high-stakes blend of hope and frustration. The approvals in May represent massive strides forward, particularly for those with specific mutations like ESR1 or HER2+. However, the path to these approvals is often fraught with regulatory hurdles that can feel detached from the urgent needs of the patient.

The Need for Continued Investment

Research does not happen in a vacuum, and it certainly does not happen without funding. METAvivor’s ability to act as a bridge during federal funding lulls depends entirely on private contributions. The implication for the broader community is clear: if we want to see the next generation of targeted therapies, we must prioritize the organizations that are funding the "high-risk, high-reward" science that big pharma or federal grants might initially overlook.

The Role of Advocacy

The Live from Stage 4 podcast serves as an essential medium for "news for us, by us." In an era of medical misinformation, providing accurate, patient-led analysis of clinical trials and regulatory meetings is a form of activism. By breaking down complex topics like the ODAC vote, these advocates are empowering patients to become active participants in their own care rather than passive recipients of medical directives.

Conclusion: A Personal and Collective Journey

As Dr. Shanahan prepares to fly from the intensity of the ASCO stage in Chicago to Nashville for her own clinical trial scans, the intersection of her personal life and her professional mission is stark. Her request for the community is twofold: for the public to support the scientific endeavor through donations and advocacy, and for a moment of solidarity as she navigates her own path through the uncertainties of treatment.

The work of METAvivor is a testament to the fact that while we cannot control the "weather" of cancer, we can build the structures necessary to withstand it. Whether through the advocacy for better trial design, the funding of critical research, or the dissemination of nuanced information, the fight against MBC is shifting from a passive wait for a cure to an aggressive, informed, and inclusive pursuit of longer, better lives.

For those interested in contributing to this effort, the doors are open. Whether by volunteering as a Patient Advocate Reviewer or contributing to the research fund, the invitation is clear: pull up a chair to the table, and let’s get to work.

References and Resources: